Dr. Hein’s research program includes studies of the molecular epidemiology of cancer susceptibility, pharmacogenetics, genomics, personalized medicine, and functional genomics. The research in molecular epidemiology identifies individuals genetically susceptible to the development of cancer from environmental and occupational chemicals in order to focus treatment and prevention public health strategies on those at greatest risk. The research in pharmacogenetics/genomics and personalized/precision medicine improves our understanding of the genetic causes for drug failure and/or drug toxicity in order to optimize clinical drug therapy for each individual patient. The research in functional genomics improves understanding of the mechanistic and clinical consequences of genetic variation in the biotransformation of carcinogens and drugs. The research program has been funded continuously since 1983 by over 75 grants and contracts totaling over $50M from the National Institutes of Health and other federal and private foundations and industry. He has coauthored over 250 , 75 gene sequences, and 600 abstracts with over 14,000 citations (h-index=60) in the scientific literature. He has presented about 150 invited research seminars in Australia, Austria, Canada, China, Czech Republic, Egypt, France, Germany, Greece, Italy, Norway, Switzerland, the United Kingdom and across the USA.
Dr. Hein was appointed as Chester Fritz Distinguished Professor at the University of North Dakota, has received outstanding teaching awards awarded by the medical school class at both Morehouse School of Medicine and the University of North Dakota, the President's Faculty Achievement Award at Morehouse School of Medicine, the Thomas J. Clifford Faculty Achievement Award for Excellence in Research and the Burlington Northern Faculty Achievement Award for Excellence in Teaching, Research, and Creative Activity both from the University of North Dakota, an Outstanding Alumnus Award from the University of Michigan, the President's Award from the University of Wisconsin-Eau Claire, and President's Outstanding Scholarship, Research and Creative Activity Awards in Basic/Applied Sciences (2003) and Career Achievement (2014) from the University of Louisville. He presented the Astor Visiting Lectureship at the University of Oxford (UK) and served as a Visiting Professor at the University of Paris Diderot. He has been elected to membership in the Academy of Pharmacology Educators of the American Society for Pharmacology and Experimental Therapeutics. As King David described in his prayer, honors are provided by the grace of our God.